Browsing Tag
Christoph Antz
2 posts
VERAXA Biotech clears final shareholder hurdle as Voyager Acquisition votes yes on $1.35bn oncology de-SPAC
Voyager Acquisition shareholders approve VERAXA Biotech combination. The cancer ADC and TCE platform heads to NASDAQ as VRXA. Read the full analysis.
VERAXA Biotech seals $1.64bn SPAC merger to launch Nasdaq oncology powerhouse
Find out how VERAXA Biotech’s $1.64B Nasdaq listing is set to redefine cancer treatment with next-gen antibody therapies.